This Common Supplement Shows Early Potential in Alzheimer's Treatment
Creatine is one of the most well-studied supplements out there. While it's best known for helping beginners boost strength and build muscle, that's just scratching the surface of what it can do. Research shows creatine also increases energy stores in the brain and may enhance cognitive function. Even more exciting? A recent study suggests it might reduce symptoms associated with Alzheimer's disease (AD).
The study, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, followed 20 patients with Alzheimer's for eight weeks. Each participant was given 20 grams of creatine (Cr) per day for the duration of the two months to see if the regimen was practical, safe, and whether it would make any noticeable difference in brain function.
To determine the effects of high-dose creatine intake, researchers used a combination of standardized cognitive assessments and blood tests. Blood tests revealed that creatine levels in the patient's blood serum increased significantly by week four and remained raised through week eight. Overall, brain creatine increased by 11%.
Remarkably, participants showed measurable improvements in several areas of cognition—including global cognition, working memory, and oral reading—suggesting that creatine has potential brain-boosting benefits beyond the gym.This isn't the first time creatine has been used to improve brain function. A different study stated that "creatine has also been shown to have antioxidant properties, reduce mental fatigue, protect the brain from neurotoxicity, and improve facets/components of neurological disorders like depression and bipolar disorder."
Research also shows that supplementing creatine can increase brain creatine stores, which is shown to enhance brain function and improve cognition. This may help explain some of the positive effects on cognition and memory shown when creatine was used by Alzheimer's patients.
Although the study published in Alzheimer's & Dementia: Translational Research & Clinical Interventions was small, the results suggest that creatine could play an important role in supporting brain health, especially in older populations.
"Determining whether AD patients benefit from CrM supplementation will require further investigation," the study authors state. "The study design limitations prevent the ability to make conclusions of efficacy; thus, we urge caution when interpreting these results. Nonetheless, our study provides the first evidence in humans that CrM supplementation is feasible and may increase brain Cr and offer cognitive benefits to patients with AD."
This Common Supplement Shows Early Potential in Alzheimer's Treatment first appeared on Men's Journal on May 23, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Sen. Warren asks for contingency plans on national security after Trump and Musk's social media fallout
Sen. Elizabeth Warren is asking Secretary of State Marco Rubio for information on the Trump administration's contingency plans if billionaire Elon Musk breaches his companies' current contracts with the U.S. amid the ongoing public fallout between him and President Trump. In a letter to Rubio as acting national security adviser and obtained by CBS News, Warren said Mr. Trump and Musk's public disagreements about the upcoming reconciliation bill that escalated into a public online spat could "have serious implications for U.S. national security." The Massachusetts Democrat mentioned Mr. Trump's proposal to terminate Musk's government contracts and subsidies, which the world's richest man followed with a threat that SpaceX would "begin decommissioning its Dragon spacecraft immediately." Musk has since walked back his threat. "No petty social media fight between the president and a billionaire should jeopardize U.S. national security," Warren said. In addition to contingency plans for SpaceX, the senator asked for information regarding the impact on U.S. agencies' satellite communications if Musk's Starlink is turned off. Additionally, she asked Rubio to provide any analysis that the Trump administration has conducted "of its authorities and options under the Defense Production Act to address vendor lock, monopolies, or contractor refusal to meet national security needs." She asked to receive answers to her questions by June 14, whether through a classified briefing or preferably a public response that can be released to Congress and the public, the letter said. Warren has been a vocal opponent of Musk and his involvement in the Trump administration. Last week, she released a report that outlines instances her office has found of Musk benefiting from it. Musk's rocket company has received tens of billions of dollars from the federal government over the last decade, including $3.8 billion in the 2024 fiscal year alone, according to federal records. The bulk of those federal grants are from NASA, which has paid SpaceX billions over the last decade to ferry astronauts and supplies to and from the International Space Station. The agency has also awarded SpaceX upwards of $2 billion in recent years to design and build a lunar lander, as part of NASA's Artemis program, which aims to return humans to the moon for the first time in a half-century. While the public spat appears to have cooled somewhat, Mr. Trump told NBC News' Kristen Welker in a phone interview on Saturday that he has no plans to make up with the mega-billionaire. "I'm too busy doing other things," Trump continued. "You know, I won an election in a landslide. I gave him a lot of breaks, long before this happened, I gave him breaks in my first administration, and saved his life in my first administration, I have no intention of speaking to him." When asked by a reporter Friday if he's still considering rolling back subsidies to Musk as a money-saving move, Mr. Trump suggested he was open to it. "He's got a lot of money, he gets a lot of subsidy. So we'll take a look at that," the president said on Air Force One. "Only if it's fair for him and for the country. I would certainly think about it, but it has to be fair." This isn't the first time the president has needled Musk over his companies' federal subsidies. In a 2022 feud, Mr. Trump claimed Musk would be "worthless" without hefty subsidies for "electric cars that don't drive long enough" and "rocketships to nowhere." The two mended their relationship then and Musk spent hundreds of millions to help elect Mr. Trump in 2024. The billionaire went on to lead the Trump White House's cost-cutting Department of Government Efficiency until last week. contributed to this report.
CBS News
an hour ago
- CBS News
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.
Medscape
2 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
